KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.98

Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.

Patricia O Guimarães, Marcelo Franken, Caio A M Tavares, Murillo O Antunes, Fabio S Silveira, Pedro B Andrade, Ricardo R Bergo, Rodrigo M Joaquim, João E Tinoco de Paula, Bruno R Nascimento, Fabio G Pitta, José A Arruda, Renato G Serpa, Louis N Ohe, Fernanda M Mangione, Remo H M Furtado, Esmeralci Ferreira, Fernanda B A Sampaio, Charlene T do Nascimento, Luiz O O Genelhu, Cristiano G Bezerra, Rogério Sarmento-Leite, Lilia N Maia, Flavio R A Oliveira, Marco V Wainstein, Frederico T C Dall'Orto, Frederico Monfardini, Silvia R L Assis, José C Nicolau, Andrei C Sposito, Renato D Lopes, Yoshinobu Onuma, Marco Valgimigli, Dominick J Angiolillo, Patrick W J C Serruys, Otavio Berwanger, Fernando Bacal, Pedro A Lemos, NEO-MINDSET Trial Investigators

N Engl J Med 393(21) 2095-2106

PMID40888723
PMCID-
DOI10.1056/NEJMoa2507980
发表日期2025-09-01
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: Whether potent P2Y12 inhibitor monotherapy without aspirin initiated shortly after successful percutaneous coronary intervention (PCI) is effective and safe for patients with acute coronary syndromes is unclear. METHODS: We conducted a multicenter, open-label, randomized trial in Brazil involving patients with acute coronary syndromes who had undergone successful PCI. Patients were assigned in a 1:1 ratio within the first 4 days of hospitalization to stop treatment with aspirin and receive potent P2Y12 inhibitor monotherapy (ticagrelor or prasugrel) or to receive dual antiplatelet therapy (aspirin and a potent P2Y12 inhibitor) for 12 months. The two ranked primary outcomes, assessed through 12 months, were a composite of death from any cause, myocardial infarction, stroke, or urgent target-vessel revascularization (tested for noninferiority, with a noninferiority margin of 2.5 percentage points) and major or clinically relevant nonmajor bleeding (tested for superiority). RESULTS: A total of 3410 patients were included in the intention-to-treat population (1712 in the monotherapy group and 1698 in the dual antiplatelet therapy group). At 12 months, death from any cause, myocardial infarction, stroke, or urgent revascularization had occurred in 119 patients (Kaplan-Meier estimate, 7.0%) in the monotherapy group and in 93 patients (Kaplan-Meier estimate, 5.5%) in the dual antiplatelet therapy group (absolute risk difference, 1.47 percentage points; 95% confidence interval [CI], -0.16 to 3.10; P = 0.11 for noninferiority). Major or clinically relevant nonmajor bleeding had occurred in 33 patients (Kaplan-Meier estimate, 2.0%) in the monotherapy group and in 82 patients (Kaplan-Meier estimate, 4.9%) in the dual antiplatelet therapy group (absolute risk difference, -2.97 percentage points; 95% CI, -4.20 to -1.73). Stent thrombosis occurred in 12 patients in the monotherapy group and in 4 in the dual antiplatelet therapy group. CONCLUSIONS: Among patients who had undergone successful PCI for acute coronary syndromes, potent P2Y12 inhibitor monotherapy was not found to be noninferior to dual antiplatelet therapy with respect to a composite of death or ischemic events at 12 months. (Funded by the Brazilian Ministry of Health; NEO-MINDSET ClinicalTrials.gov number, NCT04360720.).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。